ESM accompanying the original article “Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial” by Tonneijck L et al

ESM Fig. 3  Blood glucose response to intravenous GLP-1RA exenatide administration in overweight patients with type 2 diabetes

Blood glucose decreased after exenatide infusion by a time-averaged mean of 1.4±0.1 mmol/l compared with placebo (p<0.001).